for intravenous use Initial U.S. Approval: 2017
Imfinzi (durvalumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma (bladder cancer) and unresectable, stage III non-small cell lung cancer (NSCLC).
Facts about durvalumab injection
Disease Indications-Urothelial Carcinoma, Lung Cancer
Manufacturer-AstraZeneca Pharmaceuticals LP
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “durvalumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For durvalumab injection
Approved accessible "durvalumab injection"
Imfinzi (durvalumab) injection was initially approved in 2017. In 2022, CDER approved it to treat unresectable hepatocellular carcinoma, the most common liver cancer, together with Imjudo [see below and page 8]. In 2022, Imfinzi was also approved, in combination with chemotherapy, to treat locally advanced or metastatic biliary tract cancer, a rare and highly fatal type of cancer.
Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved by the US Food, Drug and Administration (FDA) in October 2022 for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), the most common type of liver cancer.
How can 1 go about obtaining durvalumab injection?
If durvalumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Imfinzi (durvalumab) injection for intravenous use Initial U.S. Approval: 2017
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398